Novo Nordisk’s Oral Wegovy Gains FDA Approval, 25mg Semaglutide Tablet Launches for Weight Management
The FDA approved Novo Nordisk’s 25 mg oral Wegovy semaglutide tablet for adult weight management, launching in January 2026.
Read MoreALL ABOUT DAILYZ HEALTH NEWS
ALL ABOUT DAILYZ HEALTH NEWS
The FDA approved Novo Nordisk’s 25 mg oral Wegovy semaglutide tablet for adult weight management, launching in January 2026.
Read MoreResearchers developed a DNA-based drug that activates only in cancer cells expressing two tumor markers, improving targeted treatment precision.
Read MoreA Stanford trial found a five-day monthly fasting-mimicking diet improved symptoms and remission in 69% of Crohn’s disease patients.
Read MoreA UCSF study finds aging lung cells trigger harmful immune overreactions to flu and COVID-19 in older adults, worsening lung damage.
Read MoreThe FDA set an April 23, 2026 PDUFA date for subcutaneous isatuximab in relapsed/refractory multiple myeloma, following positive phase 3 trial results.
Read MorePope Leo XIV’s decision to carry the full wooden cross through all 14 Stations at Rome’s Colosseum drew renewed attention to the connection between physical acts of religious devotion and spiritual wellness.
Read MoreA VA study found type 2 diabetes patients stopping GLP-1 drugs regained weight and faced a 22% rise in cardiovascular risks.
Read MoreDenali’s Avlayah reduced cerebrospinal fluid heparan sulfate by 91% in a Phase 1/2 trial for pediatric Hunter syndrome patients.
Read MoreThe CDC updated childhood vaccine guidelines, reducing routine immunizations from 17 to 11 diseases and shifting six vaccines to high-risk groups.
Read MoreLinguists and style experts explained that “alternative” implies mutually exclusive choices, while “option” denotes any selectable possibility.
Read More